The 2018 San Antonio Breast Cancer Symposium was held December 4 to 8 in San Antonio, Texas. This international meeting brings together scientists and clinicians who specialize in breast cancer, so they can exchange ideas in the treatment and care of people with breast cancer. In this podcast, Norah Lynn Henry, MD, PhD, shares some exciting research, from the KATHERINE clinical trial, presented at this year’s symposium about systemic treatment after surgery and standard treatment for some people with early stage, HER2-positive breast cancer.
Introduction to trastuzumab (Herceptin) and trastuzumab emtansine or T-DM1 (Kadcyla). [2:00]
Current treatment regimens using trastuzumab for HER2-positive breast cancer. [2:35]
What this study found using a treatment plan with trastuzumab emtansine for certain patients. [3:22]
What this could mean for the treatment of people who have HER2-positive breast cancer. [4:02]
Dr. Henry is an Associate Professor in the University of Utah's Division of Oncology in the Department of Medicine. She is Leader of the Women’s Cancers Disease Center of Excellence at the Huntsman Cancer Institute. Dr. Henry specializes in the care of patients with all stages of breast cancer. She is also the Cancer.Net Associate Editor for Breast Cancer.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.